Skip to content
Open access

Effectiveness and Safety of Tokishakuyakusan in Hospitalized Patients With Hypertensive Disorders of Pregnancy: A Nationwide Retrospective Cohort Study Using Japanese Claims Data

Sep 2026 · Clinical and Experimental Obstetrics & Gynecology · Vol 53 · 0 citations · 14 references

TL;DR

Tokishakuyakusan was infrequently prescribed but appeared to be safe in women with HDP and no significant association between reduced disease progression and preterm birth was identified, although the small sample size was a limiting factor.

Abstract

Background: Hypertensive disorders of pregnancy (HDP) are life-threatening conditions. Although antihypertensive medications effectively control blood pressure, they do not target the underlying pathophysiology of HDP. Tokishakuyakusan, a traditional Kampo medicine, has demonstrated the potential to improve uteroplacental circulation in experimental HDP models; however, its clinical effectiveness remains unclear. This study investigated the real-world effectiveness and safety of Tokishakuyakusan in hospitalized patients with HDP. Methods: This retrospective cohort study analyzed data from the Japanese Diagnosis Procedure Combination database collected between 2014 and 2023. Pregnant women admitted at 20 weeks of gestation or later with a diagnosis of HDP were included if they received oral antihypertensive therapy within the first 3 days of hospitalization. Patients were classified into two groups based on whether they received Tokishakuyakusan within the first 3 days of hospitalization. The primary outcome was the administration of intravenous magnesium sulfate or nicardipine. Secondary outcomes included maternal adverse events and preterm birth. Multivariate logistic regression was performed for statistical analysis. Results: Overall, 11,264 women met the inclusion criteria, including 85 who received Tokishakuyakusan in combination with antihypertensive therapy, and 11,179 who received antihypertensive drugs alone. Tokishakuyakusan use was not significantly associated with the primary outcome [adjusted odds ratio (aOR) 1.07, 95% confidence interval (CI) 0.69–1.68], maternal adverse events (aOR: 0.82, 95% CI: 0.52–1.27), or preterm birth (aOR: 0.84, 95% CI: 0.51–1.38). Conclusions: Tokishakuyakusan was infrequently prescribed but appeared to be safe in women with HDP. No significant association between reduced disease progression and preterm birth was identified, although the small sample size was a limiting factor.

Read PDF

Similar papers

Review Open access Nov 2026

EFFICACY OF ORAL NIFEDIPINE VERSUS LABETALOL IN THE EMERGENCY MANAGEMENT OF HYPERTENSIVE CRISIS IN PREGNANCY: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Oral nifedipine controls hypertensive crisis significantly faster with fewer doses than labetalol, with a moderate discriminative advantage (AUC 0.668) and equivalent maternal/perinatal safety in randomized evidence.

Made Krisna Wibawa Pramartha · 0 citations
Open access Oct 2026

Effectiveness and safety of labetalol with magnesium sulfate in preeclampsia patients and its effect on maternal and fetal outcomes: a prospective observational study at a tertiary care teaching hospital in central India

Background: Preeclampsia is a major contributor to maternal and neonatal morbidity and mortality, particularly in developing countries. Labetalol and magnesium sulfate are commonly used for blood pressure control and seizure prophylaxis, respectively. However, evidence regarding their combined effectiveness in routine...

Archishna R. Meshram, Ritu R. Kerketta, C. Shamkuwar · 0 citations
Review 2026

Comparison of the efficacy and safety of different magnesium sulfate regimens for the prevention and treatment of hypertensive disorders during pregnancy, childbirth, and the postpartum period

The use of magnesium sulfate to prevent seizures during pregnancy, childbirth, and the postpartum period in women with preeclampsia is the gold standard and is included in the clinical guidelines approved by the Ministry of Health of the Russian Federation. Although numerous studies have evaluated different regimens an...

S. Isaeva, S. Isaeva, V. Denisova et al. · 0 citations
Open access Sep 2026

Association of Antihypertensive Therapy with Preeclampsia Severity and Magnesium Sulfate Administration: A Comparative Cross-Sectional Study

Antihypertensive therapy was associated with better blood pressure control and lower odds of severe preeclampsia features and MgSO₄ administration and Prospective studies are warranted to confirm these findings.

Ammar Abed, F. Alyaseen · 0 citations
Open access Sep 2026

Characteristics of Pregnant Women with Hypertension During Pregnancy at Prof. Dr. Soekandar Hospital from January to June 2026

Hypertensive Disorders in Pregnancy (HDP) remain a major contributor to maternal morbidity and mortality worldwide. This study aimed to analyze the characteristics of pregnant women with HDP at Prof. Dr. Soekandar Hospital, Mojokerto Regency, from January to June 2026, with particular attention to Diabetes Mellitus (DM...

Mira Kusuma Wardhani · 0 citations
Open access Oct 2026

Evaluation of the risk factors in pregnant females with hypertensive disorder of pregnancy

Background: Hypertensive disorders of pregnancy (HDP) are important causes of maternal and perinatal morbidity. This study evaluated readily identifiable maternal and pregnancy-related factors associated with HDP. Methods: This analytical cross-sectional study enrolled 211 pregnant women beyond 20 weeks of gestation at...

Shashi Lata Kabra Maheshwari, Bina Kumari, Aishwarya Nandakumar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.